AdAlta Collaborated with GPCR Therapeutics for Novel Therapies to Treat Cancer
Shots:
- The companies collaborated to evaluate new cancer treatments by combining AdAlta’s CXCR4-inhibiting i-bodies with beta-blockers. AdAlta has a panel of i-bodies that suppress CXCR4 signaling. The panel contains AD-214 for fibrotic disorders that have advanced to clinical development
- AdAlta has the first option to license & commercialize products for cancer that resulted from the collaboration. GPCR has also the same option if it is not exercised by AdAlta
- The combined CXCR4-B2AR inhibition will be tested in future studies to evaluate the effect of in vitro cell signaling, migration, and killing. If the trial is successful, GPCR will test the combined inhibition of these drugs in vivo in animal cancer models
Ref: Pharmiweb | Image: AdAlta
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
